Nerelimomab

Nerelimomab (pronunciation: ne-re-li-mo-mab) is a monoclonal antibody designed for the treatment of various autoimmune diseases. It is a type of biopharmaceutical that is produced through recombinant DNA technology.

Etymology

The name "Nerelimomab" follows the INN naming convention for monoclonal antibodies. The "-mab" suffix indicates that it is a monoclonal antibody, while the prefix "Nereli-" does not have a specific meaning and is used for distinction.

Mechanism of Action

Nerelimomab works by binding to specific antigens on the surface of cells, which triggers an immune response. This can help to reduce inflammation and other symptoms associated with autoimmune diseases.

Related Terms

• Monoclonal Antibody
• Autoimmune Disease
• Antigen
• Inflammation
• Biopharmaceutical
• Recombinant DNA

See Also

• List of Monoclonal Antibodies
• List of Autoimmune Diseases

External links

• Medical encyclopedia article on Nerelimomab
• Wikipedia's article - Nerelimomab

This WikiMD dictionary article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski